Edition:
United Kingdom

argenx SE (ARGX.BR)

ARGX.BR on Brussels Stock Exchange

67.10EUR
12:37pm BST
Change (% chg)

€-1.40 (-2.04%)
Prev Close
€68.50
Open
€70.00
Day's High
€70.00
Day's Low
€67.00
Volume
124,786
Avg. Vol
68,678
52-wk High
€94.80
52-wk Low
€17.31

Select another date:

Wed, Aug 22 2018

Photo

AbbVie doubles down on cancer project with biotech group Argenx

BRUSSELS Biotech group Argenx said on Wednesday U.S. pharma group AbbVie had exercised an exclusive option to develop and commercialize one of its experimental drugs which could lead to payments of up to $625 million.

AbbVie doubles down on cancer project with biotech group Argenx

BRUSSELS Biotech group Argenx said on Wednesday U.S. pharma group AbbVie had exercised an exclusive option to develop and commercialise one of its experimental drugs which could lead to payments of up to $625 million(490.08 million pounds).

AbbVie doubles down on cancer project with biotech group Argenx

BRUSSELS, Aug 22 Biotech group Argenx said on Wednesday U.S. pharma group AbbVie had exercised an exclusive option to develop and commercialise one of its experimental drugs which could lead to payments of up to $625 million.

BRIEF-Argenx: Publication Of Study Results From Phase 1 Of FcRn-Antagonist Efgartigimod

* ANNOUNCED ON TUESDAY PUBLICATION OF FULL STUDY RESULTS FROM PHASE 1 OF FCRN-ANTAGONIST EFGARTIGIMOD (ARGX-113) IN HEALTHY VOLUNTEERS

BRIEF-Argenx Q1 Operating Income Down At 6.9 Million Euros

* ARGENX REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Argenx To Present Complete Data From Phase 2 Proof-Of-Concept Trial Of Efgartigimod (Argx-113)

* REG-ARGENX TO PRESENT COMPLETE DATA FROM PHASE 2 PROOF-OF-CONCEPT TRIAL OF EFGARTIGIMOD (ARGX-113) IN GENERALIZED MYASTHENIA GRAVIS AT AMERICAN ACADEMY OF NEUROLOGY (AAN) ANNUAL MEETING

BRIEF-Argenx To Receive Third Preclinical Milestone Payment From Collaboration With Leo Pharma

* TO RECEIVE THIRD PRECLINICAL MILESTONE PAYMENT FROM COLLABORATION WITH LEO PHARMA - MILESTONE ASSOCIATED WITH CTA APPROVAL FOR ARGX

BRIEF-Argenx Appoints Keith Woods As Chief Operating Officer

* ARGENX APPOINTS KEITH WOODS AS CHIEF OPERATING OFFICER Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Argenx Appoints Keith Woods As Chief Operating Officer

* ARGENX APPOINTS KEITH WOODS AS CHIEF OPERATING OFFICER Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Argenx ‍To Present Complete Data From Phase 2 Clinical Trial Of Efgartigimod

* ‍TO PRESENT COMPLETE DATA FROM PHASE 2 CLINICAL TRIAL OF EFGARTIGIMOD (ARGX-113) IN MYASTHENIA GRAVIS​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Select another date: